NCCN 2012 Congress Series: Skin Cancers™

Tampa, FL US
June 30, 2012

This congress is a full-day educational program designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Melanoma and Non-Melanoma Skin Cancers. Participants will learn how to implement the NCCN Guidelines recommendations into their practice and gain a clear understanding of the most up-to-date treatment recommendations for these cancers. As research continues in these areas and new information emerges, it is critical that clinicians are kept up-to-date and informed. This congress will communicate the NCCN Guidelines in a direct and interactive way to community oncologists and other clinical professionals.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this congress, participants should be able to:

NON-MELANOMA SKIN CANCERS

  • Describe the workup necessary for accurate diagnosis of MCC
  • Describe the workup necessary for accurate diagnosis of BCC
  • Outline the treatment options for different stages of MCC disease
  • Outline the treatment options for different stages of BCC disease
  • Stratify patients with cutaneous SCC according to risk of recurrence
  • Outline the appropriate treatment for each cutaneous SCC risk category
  • Select appropriate treatment options for recurrent or metastatic SCC disease

MELANOMA

  • Counsel patients with in-transit metastases on the different local treatment options available
  • Discuss the role of ipilimumab immunotherapy in metastatic disease and monitoring of side effects;
  • Describe the specific indication for vemurafenib and the necessary dermatologic surveillance
  • Discuss the molecular workup for accurate diagnosis of melanoma
  • Identify the essential components of a pathology report for melanoma
Additional information
Supporters: 

This activity is supported by educational grants from Bristol-Myers Squibb and Genentech.

Course summary
Available credit: 
  • 5.75 Participation
  • 5.91 Nurse
  • 5.75 Pharmacist
  • 5.75 Physician
Course opens: 
06/30/2012
Course expires: 
11/17/2012
Event starts: 
06/30/2012 - 7:45am
Event ends: 
06/30/2012 - 3:30pm
Cost:
$0.00
Moffitt Cancer Center
Stabile Research Building
12902 Magnolia Drive
Tampa, FL 33612
United States

Agenda

7:00 – 7:45 AM
Registration

7:45 – 8:00 AM
Welcome
Thomas A. Sellers, PhD
Director, Moffitt Research Institute
Executive Vice President
H. Lee Moffitt Cancer Center & Research Institute

NON-MELANOMA

8:00 – 9:00 AM
Management of Basal Cell and Squamous Cell Carcinoma of the Skin
Stanley J. Miller, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

9:05 – 10:05 AM
Management of Merkel Cell Carcinoma
Paul Nghiem, MD, PhD
Fred Hutchinson Cancer Research Center

Richard T. Cheney, MD
Roswell Park Cancer Institute

10:05 – 10:25 AM
Break

MELANOMA

10:25 – 11:25 AM
Local Therapy in Melanoma
Daniel G. Coit, MD
Memorial Sloan-Kettering Cancer Center

11:30 AM – 12:05 PM
Pathology Issues in Melanoma
L. Frank Glass, MD
H. Lee Moffitt Cancer Center & Research Institute

12:05 – 12:55 PM
Lunch

12:55 – 1:30 PM
Molecular Diagnostics in Melanoma
Vernon K. Sondak, MD
H. Lee Moffitt Cancer Center & Research Institute

1:35 – 2:35 PM
Treatment of Metastatic Melanoma
Anthony J. Olszanski, MD
Fox Chase Cancer Center

2:40 – 3:25 PM
New Agents in Development for Melanoma
Jeffrey Weber, MD, PhD
H. Lee Moffitt Cancer Center & Research Institute

3:25 – 3:30 PM
Closing Remarks

Available Credit

  • 5.75 Participation
  • 5.91 Nurse
  • 5.75 Pharmacist
  • 5.75 Physician

Accreditation Period

Course opens: 
06/30/2012
Course expires: 
11/17/2012

Price

Cost:
$0.00
Please login or register to take this course.